Abstract
Goal of work
The aim of this study was to compare palifermin, a recombinant form of human keratinocyte growth factor, with standard treatment on outcomes in patients receiving a high dose of chemotherapy conditioning regimen, undergoing hematopoietic stem cell transplantation (HSCT).
Materials and methods
Over a 1-year period, a series of 59 patients were included: 32 patients (palifermin) were compared with 27 patients (standard treatment). Outcomes assessed at day 8 posttransplantation were mucositis, swallowing, nutrition impact symptoms, dietary intake, time to engraftment, length of stay, infection, and cumulative dose and duration of narcotic administration.
Main results
There was a significant reduction in the incidence of severe oral mucositis (13 vs 48%, p=0.003), swallowing problems (p=0.044), number of nutrition impact symptoms experienced (4.9 vs 6.0, p=0.003), and length of stay (14 vs 18 days, p=0.026) in the palifermin group compared to standard care. There was no significant difference in infection, dietary intake, time to engraftment or cumulative dose and duration of narcotic administration between groups.
Conclusions
Beneficial outcomes were observed from the use of palifermin in patients undergoing HSCT after a high dose of chemotherapy conditioning regimen. A randomized clinical trial is needed to confirm these results.
References
Adis Data Information BV (2004) Palifermin. Drugs R D 5:351–354
Horsley P, Bauer J, Gallagher B (2005) Poor nutritional status prior to peripheral blood stem cell transplantation is associated with increased length of hospital stay. Bone Marrow Transplant 35:1113–1116
Isenring, E, Bauer J, Capra S (2003) The scored Patient-Generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr 57:305–309
Lipkin AC, Lenssen P, Dickson BJ (2005) Nutrition issues in hematopoietic stem cell transplantation: state of the art. Nutr Clin Pract 20:423–439
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting the results of cancer treatment. Cancer 47:207–214
Multinational Association of Supportive Care in Cancer (2005) Mucositis: perspectives and clinical practice guidelines. http://www.mascc.org/index.php?load=pro_study_groups&page_id=73 (June 2005 update)
Osoba, D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
Ottery F (2000) Patient-generated subjective global assessment. In: McCallum P, Polisena C (eds) The clinical guide to oncology nutrition. American Dietetic Association, Chicago, pp 11–23
Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM (2004) Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22:1268–1275
Rubenstein E, Peterson D, Schubert M, Keefe D, McGuire D, Epstein J (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:S2026–S2046
Sonis S (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205
Sonis S, Elting L, Keefe D, Peterson D, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer—therapy induced mucosal injury. Cancer 100:S1995–S2025
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2599
Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazer B, Shea TC et al (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol (in press). DOI 10.1200/JCO.2005.02.8340
Acknowledgment
Thank you to AMGEN for the supply of palifermin.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Horsley, P., Bauer, J.D., Mazkowiack, R. et al. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 15, 105–109 (2007). https://doi.org/10.1007/s00520-006-0105-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-006-0105-y